Table 1 Characteristics of cohorts and participants included in analyses
CohortCombined
Côte d’Ivoire (Abidjan)Uganda (Masaka)Uganda (Rakai)Thailand (Royal Thai Army)Thailand (Chiang Mai)
ReferenceMinga et al9Morgan et al32Wawer et al33Rangsin et al12Nagachinta et al13
Study populationBlood donorsParticipants in community cohortParticipants in community cohortMilitary conscriptsMale blood donors and their female partners
Year of start of study19971990199119981992
No of participants included in analyses (%)253 (100)338 (100)411 (100)233 (100)837 (100)2072 (100)
Median (IQR) interval between last negative and first positive HIV-1 test, months7.5 (3.4–19.1)12.5 (11.7–24.3)22.4 (14.6–37.7)8.5 (5.7–9.5)50.7 (31.6–69.8)24.0 (11.8–50.1)
No of women (%)97 (38.3)180 (53.2)256 (62.3)0 (0)267 (31.9)800 (38.6)
No of patients starting ART (%)79 (31.2)57 (16.9)151 (36.7)0 (0)0 (0)287 (13.8)
Mean (SD) age at baseline, years29.1 (7.1)32.0 (13.6)35.8 (2.5)22.1 (0.9)28.7 (6.4)29.9 (8.3)
Median (IQR) baseline CD4 cell count (IQR), cells ×106/l472 (331–648)553 (425–743)409 (235–584)NANA
Median (IQR) number of CD4 counts per person9 (5–14)5 (2–11)3 (2–7)NANA
Median (IQR) follow up from seroconversion, years5.4 (5.4–7.6)4.9 (3.3–7.8)5.7 (3.8–7.6)6.0 (5.3–6.7)6.5 (5.2–9.1)6.0 (4.4–7.8)
  • NA, not systematically assessed and therefore not analysed in this study; SD, standard deviation; IQR, interquartile range.

  • The baseline CD4 count relates to the first measurement after seroconversion.